January 19, 2026 a 05:00 pm
BAX: Analysts Ratings - Baxter International Inc.
Baxter International Inc. is facing a complex landscape with mixed analyst ratings. While the company's diverse healthcare portfolio offers strong long-term potential, recent sentiments suggest a cautious approach. The growth in 'Hold' ratings could indicate uncertainty amid strategic challenges and evolving market dynamics. Investors are advised to monitor quarterly results closely to assess financial resilience and strategic execution.
Historical Stock Grades
| Rating Type | Number of Ratings | Score Visual |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 2 | |
| Hold | 13 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, there has been a marked increase in 'Hold' ratings, indicating potential caution among analysts. While 'Strong Buy' and 'Buy' ratings have seen minor fluctuations, the dominant sentiment leans towards maintaining positions rather than selling or increasing stakes.
- The overall volume of analyst ratings has remained fairly stable.
- A noticeable trend is the steady incline in 'Hold' ratings since mid-2024.
- 'Strong Buy' and 'Buy' ratings have seen a minor decline, reflecting a shift towards conservatism.
Percentage Trends
The percentage analysis of analyst ratings reveals a shift towards a more cautious sentiment. The proportion of 'Hold' ratings now significantly outweighs others, suggesting a period of uncertainty or awaited developments before any decisive actions.
- The 'Strong Buy' category has dropped from 22% to about 5% over the last year.
- 'Buy' recommendations also reflect a downward trend, from 39% to approximately 10% of total ratings.
- 'Hold' ratings increased substantially from 31% to over 80%, demonstrating growing caution.
Latest Analyst Recommendations
Recent analyst recommendations for Baxter International Inc. have conveyed a consistent sentiment. The majority are maintaining their current rating stance, reflecting a cautious attitude toward significant market shifts.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-09 | Overweight | Overweight | Barclays |
| 2025-12-02 | Underweight | Underweight | Morgan Stanley |
| 2025-10-31 | Neutral | Neutral | UBS |
| 2025-10-31 | Hold | Buy | Argus Research |
| 2025-10-31 | Neutral | Neutral | Goldman Sachs |
Analyst Recommendations with Change of Opinion
A shift in market sentiment is evident as several analysts have revised their outlook on Baxter International Inc. The downgrades suggest a reevaluation of the company's prospects amidst external market and internal strategic influences.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-31 | Hold | Buy | Argus Research |
| 2025-08-04 | Hold | Buy | Stifel |
| 2024-07-15 | Underweight | Equal Weight | Morgan Stanley |
| 2024-05-10 | Hold | Buy | TD Cowen |
| 2023-01-06 | Equal Weight | Overweight | Morgan Stanley |
Interpretation
The comprehensive analysis of Baxter International Inc.'s analyst ratings suggests a conservative market stance. The substantial rise in 'Hold' ratings indicates a wait-and-see approach amid uncertain market conditions and strategic realignments within the company. Changes in analyst opinions, alongside stable 'Neutral' and 'Underweight' stances, point towards a cautious outlook rather than aggressive investment. Such sentiments suggest that investors may want to evaluate potential risks associated with market volatilities and strategic execution paths before making decisions.
Conclusion
Baxter International Inc. faces a mixed analytical landscape, driven largely by external market factors and internal strategic transitions. Although the company's fundamental strengths, such as its comprehensive healthcare portfolio, offer long-term growth potential, current analyst sentiment indicates a period of caution. The shift from active buying towards neutrality suggests the market is waiting for clearer signals of stability and strategic follow-through. Investors should keep an eye on quarterly reports for signs of financial robustness and alignment with strategic objectives, balancing optimism with prudent risk management.